Prescribing information and adverse event reporting information for EYLEA® (aflibercept) can be accessed here or via the QR code located on the last page of this document.

EYLEA® 8mg
(aflibercept 114.3mg/mL, solution for injection)

EYLEA® (aflibercept) 8 mg DOSING REGIMENS IN nAMD AND DMO

EYLEA 8 mg is the first and only anti-VEGF in nAMD and DMO that allows for extensions up to Q20,* with a safety profile comparable to EYLEA 2 mg. So you can confidently extend treatment intervals to help optimise your clinic's capacity.[1–5]

***Following 3 monthly loading doses, intervals can be extended to Q16, dependent on visual and/or anatomic outcomes, and subsequently to Q20 (e.g. with a T&E regimen) if visual and/or anatomic outcomes are stable. Consult the SmPC for full posology.[5]**

EYLEA 114.3 mg/mL is indicated in adults for the treatment of neovascular (wet) age-related macular degeneration (nAMD) and visual impairment due to diabetic macular oedema (DMO).[5]

For UK healthcare professionals only.

DMO, diabetic macular oedema. nAMD, neovascular age-related macular degeneration. Q16, every 16 weeks. Q20, every 20 weeks. SmPC, Summary of Product Characteristics. T&E, treat and extend. VEGF, vascular endothelial growth factor.

References

1. Korobelnik J-F. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 48-week results from the Phase 3 PULSAR trial. Retina Society. 2–5 November 2022. Pasadena, USA. Oral presentation. **2.** Do D. Aflibercept 8 mg for diabetic macular edema: 48-week results from the Phase 2/3 PHOTON trial. ARVO. 23–27 April 2023. Palo Alto, USA. Oral presentation. **3.** Lanzetta P. Intravitreal aflibercept 8 mg injection in patients with neovascular age-related macular degeneration: 60-week and 96-week results from the Phase 3 PULSAR trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation. **4.** Wykoff CC. Aflibercept 8 mg for diabetic macular edema: 96-week results from the Phase 2/3 PHOTON trial. EURETINA. 5–8 October 2023. Amsterdam, The Netherlands. Oral presentation. **5.** EYLEA® 114.3 mg/mL Summary of Product Characteristics.

PP-EYL_8mg-GB-0339 | December 2024

TREAT YOUR ELIGIBLE PATIENTS WITH SIMPLICITY

Extend to Q16 dosing directly after only 3 loading doses in both nAMD and DMO with EYLEA 8 mg[1]

After reaching Q16, patients can be extended to Q20*



Dosing diagram for illustrative purposes only.

***EYLEA treatment is initiated with 1 injection per month for 3 consecutive doses. Injection intervals may then be extended up to every 4 months based on the physician's judgement of visual and/or anatomic outcomes. Subsequently, the treatment intervals may be further extended up to 5 months, such as with a T&E dosing regimen, while maintaining stable visual and/or anatomic outcomes (see SmPC section 5.1).[1]**

If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly based on the physician's discretion. The shortest interval between 2 injections is 2 months in the maintenance phase.[1]

The recommended dose is 8 mg aflibercept, equivalent to 0.07 mL solution. The posology is the same for the nAMD and DMO indications. The 8 mg dose requires use of the EYLEA 114.3 mg/ml vial.[1]

EYLEA at monthly doses of 8 mg has not been studied for more than 3 consecutive doses.[1]

The frequency of monitoring visits should be based on the patient's status and at the physician's discretion.[1]

DMO, diabetic macular oedema. nAMD, neovascular age-related macular degeneration. Q16, every 16 weeks. Q20, every 20 weeks. SmPC, Summary of Product Characteristics. T&E, treat and extend.

Reference: 1. EYLEA® 114.3 mg/mL Summary of Product Characteristics.

TREAT YOUR ELIGIBLE PATIENTS WITH SIMPLICITY

Extend to Q12 dosing directly after only 3 loading doses in both nAMD and DMO with EYLEA 8 mg[1]*



Dosing diagram for illustrative purposes only.

***EYLEA treatment is initiated with 1 injection per month for 3 consecutive doses. Injection intervals may then be extended up to every 4 months based on the physician's judgement of visual and/or anatomic outcomes. Subsequently, the treatment intervals may be further extended up to 5 months, such as with a T&E dosing regimen, while maintaining stable visual and/or anatomic outcomes (see SmPC section 5.1).[1]**

If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly based on the physician's discretion. The shortest interval between 2 injections is 2 months in the maintenance phase.[1]

The recommended dose is 8 mg aflibercept, equivalent to 0.07 mL solution. The posology is the same for the nAMD and DMO indications. The 8 mg dose requires use of the EYLEA 114.3 mg/ml vial.[1]

EYLEA at monthly doses of 8 mg has not been studied for more than 3 consecutive doses.[1]

The frequency of monitoring visits should be based on the patient's status and at the physician's discretion.[1]

DMO, diabetic macular oedema. nAMD, neovascular age-related macular degeneration. Q12, every 12 weeks. SmPC, Summary of Product Characteristics. T&E, treat and extend.

Reference: 1. EYLEA® 114.3 mg/mL Summary of Product Characteristics.

TREAT YOUR ELIGIBLE PATIENTS WITH SIMPLICITY

The flexibility to use your clinic's extension method, such as T&E[1]

After reaching Q16, patients can be extended to Q20*



Dosing diagram for illustrative purposes only.

***EYLEA treatment is initiated with 1 injection per month for 3 consecutive doses. Injection intervals may then be extended up to every 4 months based on the physician's judgement of visual and/or anatomic outcomes. Subsequently, the treatment intervals may be further extended up to 5 months, such as with a T&E dosing regimen, while maintaining stable visual and/or anatomic outcomes (see SmPC section 5.1).[1]**

If visual and/or anatomic outcomes deteriorate, the treatment interval should be shortened accordingly based on the physician's discretion. The shortest interval between 2 injections is 2 months in the maintenance phase.[1]

The recommended dose is 8 mg aflibercept, equivalent to 0.07 mL solution. The posology is the same for the nAMD and DMO indications. The 8 mg dose requires use of the EYLEA 114.3 mg/ml vial.[1]

EYLEA at monthly doses of 8 mg has not been studied for more than 3 consecutive doses.[1]

The frequency of monitoring visits should be based on the patient's status and at the physician's discretion.[1]

DMO, diabetic macular oedema. nAMD, neovascular age-related macular degeneration. Q8, every 8 weeks. Q12, every 12 weeks. Q16, every 16 weeks. Q20, every 20 weeks. SmPC, Summary of Product Characteristics. T&E, treat and extend.

Reference: 1. EYLEA® 114.3 mg/mL Summary of Product Characteristics.

Prescribing information and adverse event reporting information for EYLEA® (aflibercept) is available via the QR code on the right.

Either click **here** or scan the QR code for prescribing information and adverse event reporting information.

For direct access to this prescribing information, please ensure your device's browser settings have automatic PDF download enabled.